Acumen Pharmaceuticals, Inc. Operating Cash Flow
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Cash Flow of -$42.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.07M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$24.13M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$19.10M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$30.49M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$115.54M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$86.22M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$43.06M.
- Acumen Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$35.15M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$42.20M 10-Q · filed 2026-08-12 | -$61.30M derived: sum of 3 quarters · filed 2026-08-12 | -$91.79M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$24.13M 10-Q · filed 2026-05-12 | -$43.22M derived: sum of 2 quarters · filed 2026-05-12 | -$73.71M derived: sum of 3 quarters · filed 2026-05-12 | -$105.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$19.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$49.59M derived: sum of 2 quarters · filed 2026-03-26 | -$81.42M derived: sum of 3 quarters · filed 2026-08-12 | -$115.54M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$30.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$62.32M derived: sum of 2 quarters · filed 2026-08-12 | -$96.44M 10-Q · filed 2025-11-12 | -$123.66M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$31.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$65.95M 10-Q · filed 2026-08-12 | -$93.17M derived: sum of 3 quarters · filed 2026-08-12 | -$117.76M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$34.12M 10-Q · filed 2026-05-12 | -$61.34M derived: sum of 2 quarters · filed 2026-05-12 | -$85.93M derived: sum of 3 quarters · filed 2026-05-12 | -$102.48M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$27.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$51.81M derived: sum of 2 quarters · filed 2026-03-26 | -$68.36M derived: sum of 3 quarters · filed 2026-03-26 | -$86.22M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$24.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$41.14M derived: sum of 2 quarters · filed 2025-11-12 | -$59.00M 10-Q · filed 2025-11-12 | -$67.31M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$34.40M 10-Q · filed 2025-08-12 | -$42.72M derived: sum of 3 quarters · filed 2025-08-12 | -$55.62M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$17.86M 10-Q · filed 2025-05-13 | -$26.17M derived: sum of 2 quarters · filed 2025-05-13 | -$39.08M derived: sum of 3 quarters · filed 2025-05-13 | -$50.75M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$8.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$21.22M derived: sum of 2 quarters · filed 2025-03-27 | -$32.89M derived: sum of 3 quarters · filed 2025-03-27 | -$43.06M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$12.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$24.57M derived: sum of 2 quarters · filed 2024-11-12 | -$34.75M 10-Q · filed 2024-11-12 | -$45.95M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$11.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$21.84M 10-Q · filed 2024-08-13 | -$33.05M derived: sum of 3 quarters · filed 2024-08-13 | -$42.23M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$10.18M 10-Q · filed 2024-05-14 | -$21.38M derived: sum of 2 quarters · filed 2024-05-14 | -$30.56M derived: sum of 3 quarters · filed 2024-05-14 | -$37.03M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$20.39M derived: sum of 2 quarters · filed 2024-03-26 | -$26.85M derived: sum of 3 quarters · filed 2024-03-26 | -$35.15M 10-K · filed 2024-03-26 |
| 2022-09-30 | -$9.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$15.65M derived: sum of 2 quarters · filed 2023-11-13 | -$23.95M 10-Q · filed 2023-11-13 | -$27.59M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$14.77M 10-Q · filed 2023-08-08 | -$18.41M derived: sum of 3 quarters · filed 2023-08-08 | -$26.09M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$8.30M 10-Q · filed 2023-05-09 | -$11.94M derived: sum of 2 quarters · filed 2023-05-09 | -$19.63M derived: sum of 3 quarters · filed 2023-05-09 | -$23.89M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$3.64M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$11.33M derived: sum of 2 quarters · filed 2023-03-27 | -$15.59M derived: sum of 3 quarters · filed 2023-03-27 | -$17.96M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$7.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$11.95M derived: sum of 2 quarters · filed 2022-11-14 | -$14.32M 10-Q · filed 2022-11-14 | -$17.18M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$4.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$6.63M 10-Q · filed 2022-08-15 | -$9.49M derived: sum of 3 quarters · filed 2022-08-15 | -$10.77M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$2.37M 10-Q · filed 2022-05-16 | -$5.23M derived: sum of 2 quarters · filed 2022-05-16 | -$6.51M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$2.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$4.14M derived: sum of 2 quarters · filed 2022-03-28 | -$7.45M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | -$4.59M 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$3.31M 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |